Loading...
Patients with peripheral arterial disease have an increased risk for cardiovascular events. In response to great interest in strategies that might reduce that risk, investigators from seven countries tested whether the combination of antiplatelet and anticoagulant therapy is superior to antiplatelet therapy alone at reducing the risk for cardiovascular death, MI, stroke, or severe ischemia of the coronary or peripheral arteries necessitating intervention. The Warfarin Antiplatelet Vascular Evaluation (WAVE) trial investigators randomized 2161 patients (mean age, 64; 73.6% men) who had peripheral arterial disease but were not at high risk for bleeding and had no recent stroke, dialysis treatment, or other indication for oral anticoagulation.…